Associated Papers
Transcriptomic Alteration in FUS-ALS Points Towards Apoptosis-Rather than Ferroptosis-Related Cell Death Pathway.
Dash BP et al.
Cells, 2025
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X et al.
Cell Death & Disease, 2022
Ser392 phosphorylation modulated a switch between p53 and transcriptional condensates.
Dai Z et al.
Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms, 2022
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.
Ben-Cohen G et al.
Briefings in Bioinformatics, 2022
STING-mediated degradation of IFI16 negatively regulates apoptosis by inhibiting p53 phosphorylation at serine 392.
Li D et al.
The Journal of Biological Chemistry, 2021
How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor.
Ho T et al.
International Journal of Molecular Sciences, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Regulators of Oncogenic Mutant TP53 Gain of Function.
Yamamoto S et al.
Cancers, 2018
Serine 392 phosphorylation modulates p53 mitochondrial translocation and transcription-independent apoptosis.
Castrogiovanni C et al.
Cell Death and Differentiation, 2018
Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells.
Liu K et al.
Molecular Cell, 2017
FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Li N et al.
Oncotarget, 2015
Structural and sequential context of p53: A review of experimental and theoretical evidence.
Saha T et al.
Progress in Biophysics and Molecular Biology, 2015
Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters.
Loughery J et al.
Nucleic Acids Research, 2014
Mutant TP53 posttranslational modifications: challenges and opportunities.
Nguyen TA et al.
Human Mutation, 2014
Insights into wild-type and mutant p53 functions provided by genetically engineered mice.
Donehower LA
Human Mutation, 2014
The rebel angel: mutant p53 as the driving oncogene in breast cancer.
Walerych D et al.
Carcinogenesis, 2012
A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation.
Piccinin S et al.
Cancer Cell, 2012
Abl interconnects oncogenic Met and p53 core pathways in cancer cells.
Furlan A et al.
Cell Death and Differentiation, 2011
Transcriptional regulation of HIV-1 gene expression by p53.
Mukerjee R et al.
Cell Cycle (georgetown, Tex.), 2010
p53 post-translational modification: deregulated in tumorigenesis.
Dai C et al.
Trends in Molecular Medicine, 2010
Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53.
Prowald A et al.
The Prostate, 2007
TSH signalling and cancer.
García-Jiménez C et al.
Arquivos Brasileiros De Endocrinologia E Metabologia, 2007
Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus.
Karni-Schmidt O et al.
Oncogene, 2007
p53 alterations in human cancer: more questions than answers.
Soussi T
Oncogene, 2007
LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation.
Zeng PY et al.
Cancer Research, 2006
Cdk9 phosphorylates p53 on serine 392 independently of CKII.
Claudio PP et al.
Journal of Cellular Physiology, 2006
Structural basis for gene activation by p53 family members.
Scoumanne A et al.
Cancer Biology & Therapy, 2005
A differential proteomic approach to identify proteins associated with thyroid cell transformation.
Paron I et al.
Journal of Molecular Endocrinology, 2005
Functional protein microarrays for parallel characterisation of p53 mutants.
Boutell JM et al.
Proteomics, 2004
Binding of RNA to p53 regulates its oligomerization and DNA-binding activity.
Yoshida Y et al.
Oncogene, 2004
DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage.
Jack MT et al.
The Journal of Biological Chemistry, 2004
The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage.
Okorokov AL et al.
Oncogene, 2002
A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.
Keller DM et al.
Molecular Cell, 2001
Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner.
Stewart ZA et al.
Oncogene, 2001
The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro.
Cuddihy AR et al.
Oncogene, 1999
DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation.
Blattner C et al.
Oncogene, 1999
Cdk2 kinase phosphorylates serine 315 of human p53 in vitro.
Price BD et al.
Oncogene, 1995
The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
Fiscella M et al.
Oncogene, 1994
Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation.
Malcikova J et al.
Biological Chemistry, 0